Category Archives: Cell Therapy

(PRWEB) May 02, 2014

The report Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020 analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Asia-Pacific, Europe, and the Rest of the World (RoW).

Browse 57 market data tables 32 figures spread through 196 Slides and in-depth TOC on Stem Cell Therapy Market http://www.marketsandmarkets.com/Market-Reports/stem-cell-technologies-and-global-market-48.html

Early buyers will receive 10% customization on report.

This report studies the global stem cell therapy market over the forecast period of 2015 to 2020.The market is poised to grow at a CAGR of 39.5% from 2015 to 2020, to reach $330million by 2020.

Download Free PDF Download @ http://www.marketsandmarkets.com/pdfdownload.asp?id=48

The global stem cell therapy market on the basis of the mode of treatment is segmented into allogeneic and autologous stem cell therapy. In addition, based on the therapeutic applications, the global stem cell therapy market is segmented into eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others.

Inquire Before Buying @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=48

A number of factors such as the increasing funding from various government and private organizations, growing industry focus on stem cell research, and increasing global awareness about stem cell therapies through various organizations are stimulating the research activities for stem cell therapies. Developing markets, emergence of induced pluripotent stem (iPS) cells as an alternative to embryonic stem cells (ESCs), and evolution of new stem cell therapies represent high growth opportunities for market players.

In 2015, North America will hold the largest share of the global stem cell therapy market. This large share is primarily attributed to the extensive government funding and increasing fast-track approval for stem cell therapeutics by the FDA. Moreover, development of advanced genomic methods for stem cell analysis and high number of ongoing research activities are further fueling the growth of the stem cell therapy market in North America. However, the Asia-Pacific stem cell therapy market is expected to grow at the highest CAGR in the forecast period, owing to factors such as increasing regulatory support through favorable government policies, strong product pipelines, and increasing licensing activities in this region.

Go here to read the rest:
Stem Cell Therapy Market (Autologous & Allogeneic) Worth $330 Million in 2020 - New Report by MarketsandMarkets

A new review of previous scientific studies has concluded that stem cell therapy may help reduce the number of deaths in heart patients.

The Cochrane Heart Review Group analyzed data from studies involving just over 1,200 patients in 23 randomized, controlled trials.

The group's report on the potential benefits of stem cell heart repair was published online on April 29 in The Cochrane Library. The Cochrane Reviews are systematic assessments of evidence-based research into human health care and health policy.

There were fewer deaths among heart patients receiving stem cell therapy in addition to standard treatment, compared to patients who were treated with traditional therapies alone or with a placebo. Stem cells are primitive master cells that, under the right conditions, can turn into any cell in the body.

The therapy also reduced the chances that patients, with improved heart function, had to be readmitted to the hospital.

The review noted that stem cell therapy could possibly reduce the number of deaths after one year, but the results of larger clinical trials are needed.

The stem cells are taken from a patients own bone marrow and injected into the hearts of patients with ischemic heart disease and congestive heart failure, repairing damaged cardiac tissue.

Dr. Enca Martin-Rendon, author of the review in Britain, said, This is encouraging evidence that stem cell therapy has benefits for heart disease patients. However, Martin-Rendon noted it is difficult to come to any concrete conclusions until larger clinical trials are carried out.

Read the original post:
Stem Therapy May Improve Survival of Heart Patients

An implanted graft of cardiac cells derived from human stem cells (green) meshed with a monkey's own heart cells (red). Picture: Murry Lab/University of Washington/PA

Stem cell heart repair treatments could be tested on human patients within four years following a ground-breaking study of monkeys.

Scientists successfully restored damaged cardiac muscle in macaque monkeys suffering the after-effects of experimentally induced heart attacks, paving the way to clinical trials.

Researchers injected 1bn immature heart muscle cells derived from human embryonic stem cells into each animals heart.

Over several weeks, the new cells developed, assembled into muscle fibres, and began to beat in correct time. On average, 40% of the damaged heart tissue was regenerated.

It is the first time stem cell therapy for damage caused by heart attacks has been shown to work in a primate.

Lead scientist Prof Charles Murry, director of the Centre for Cardiovascular Biology at the University of Washington in Seattle, said: Before this study, it was not known if it is possible to produce sufficient numbers of these cells and successfully use them to remuscularise damaged hearts in a large animal whose heart size and physiology is similar to that of the human heart.

He expects the treatment to be ready for clinical trials in human patients within four years.

Heart attack symptoms were triggered in the monkeys by blocking the coronary artery the main artery supplying the heart with blood for 90 minutes.

In humans, the reduced blood flow caused by narrowing of the arteries has a similar effect. Lack of blood flow to the heart damages the heart muscle by depriving it of oxygen.

Read more from the original source:
Stem cell breakthrough in treating heart attacks

Home > News > health-news

Sydney, May 1 : The humble teeth can come to rescue your brain. Researchers at University of Adelaide have discovered that stem cells taken from teeth can grow to resemble brain cells and can be used in the brain as a therapy for stroke.

"Stem cells from teeth have great potential to grow into new brain or nerve cells and this could potentially assist with treatments of brain disorders, such as stroke," explained Kylie Ellis, a commercial development manager with the University's Adelaide Research & Innovation (ARI).

In the University's centre for stem cell research, lab studies have shown that stem cells from teeth can develop and form complex networks of brain-like cells.

The reality is that treatment options available to the thousands of stroke patients every year are limited.

"Ultimately, we want to be able to use a patient's own stem cells for tailor-made brain therapy that does not have the host rejection issues commonly associated with cell-based therapies," Ellis noted.

Another advantage is that dental pulp stem cell therapy may provide a treatment option available months or even years after the stroke has occurred, she added.

"We can do this by providing an environment for the cells that is as close to a normal brain environment as possible, so that instead of becoming cells for teeth, they become brain cells," Ellis maintained.

This work with dental pulp stem cells opens up the potential for modelling many more common brain disorders in the laboratory, which could help in developing new treatments and techniques for patients.

The results of her work were published in the journal Stem Cell Research & Therapy.

Read the original:
Teeth stem cells can help treat brain stroke

Stem Cell Treatment In Panama Working Wonders
This is an update on Beverly after only 10 days in Panama for Stem Cell Treatment. She is feeling so much better and you can see it just by the look on her face. She has Secondary Progressive...

By: Stem Cell Patient

See original here:
Stem Cell Treatment In Panama Working Wonders - Video

Chaiwat Subprasom/Reuters/Corbis

Many companies around the world offer stem-cell treatments to patients with heart disease.

An analysis of clinical studies that use adult stem cells to treat heart disease has raised questions about the value of a therapy that many consider inappropriately hyped.

Early-phase clinical trials have reported that adult stem cells are effective in treating heart attack and heart failure, and many companies are moving quickly to tap into this potentially lucrative market. But a comprehensive study that looked at discrepancies in trials investigating treatments that use patients own stem cells, published this week in the journal BMJ (ref. 1), finds that only trials containing flaws, such as design or reporting errors, showed positive outcomes. Error-free trials showed no benefit at all.

The publication comes as two major clinical trials designed to conclusively test the treatments efficacy are recruiting thousands of patients.

The BMJ paper is concerning because the therapeutic approach is already being commercialized, argues stem-cell researcher Paolo Bianco at the Sapienza University of Rome. Premature trials can create unrealistic hopes for patients, and divert resources from the necessary basic studies we need to design more appropriate treatments.

Therapies that use adult stem cells typically involve collecting mesenchymal stem cells from bone marrow taken from the patients hip bone. The cells are then injected back into the patient, to help repair damaged tissue. Original claims that they differentiated into replacement cells have been rejected2, and many clinicians now believe that the cells act by releasing molecules that cause inflammation, with an attendant growth of oxygen-delivering small blood vessels, in the damaged tissue.

The approach has spawned international commercialization of various forms of the therapy, with companies offering treatments for disorders ranging from Parkinsons disease to heart failure. But the effectiveness of such therapies remains unproven.

I have a lot of hope for regenerative medicine, but our results make me fearful.

The BMJ study, led by cardiologist Darrel Francis at Imperial College London, examined 133 reports of 49 randomized clinical trials published up to April last year, involving the treatment of patients who had had a heart attack or heart failure. It included all accessible randomized studies, and looked for discrepancies in design, methodology and reporting of results.

Original post:
Doubts over heart stem-cell therapy